North America Pediatric Cancer Biomarker Market Size & Outlook

The pediatric cancer biomarker market in North America is expected to reach a projected revenue of US$ 616.9 million by 2030. A compound annual growth rate of 8.1% is expected of North America pediatric cancer biomarker market from 2024 to 2030.
Revenue, 2023 (US$M)
$357.6
Forecast, 2030 (US$M)
$616.9
CAGR, 2024 - 2030
8.1%
Report Coverage
North America

North America pediatric cancer biomarker market, 2018-2030 (US$M)

North
Unlock Premium

North America pediatric cancer biomarker market highlights

  • The North America pediatric cancer biomarker market generated a revenue of USD 357.6 million in 2023.
  • The market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
  • In terms of segment, leukemia was the largest revenue generating indication in 2023.
  • Leukemia is the most lucrative indication segment registering the fastest growth during the forecast period.


North America data book summary

Market revenue in 2023USD 357.6 million
Market revenue in 2030USD 616.9 million
Growth rate8.1% (CAGR from 2023 to 2030)
Largest segmentLeukemia
Fastest growing segmentLeukemia
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationLeukemia


Other key industry trends

  • In terms of revenue, North America region accounted for 43.8% of the global pediatric cancer biomarker market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 348.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pediatric Cancer Biomarker Market Scope

Pediatric cancer biomarker market segmentation & scope
Neuroblastoma
CNS Tumors
Lymphona
Others
Biomarker
Alpha - fetoprotein (AFP)
Neuron - specific enolase (NSE)
CD19, CD20, CD22
ALK (anaplastic lymphoma receptor tyrosine kinase gene)
Others
End Use
Hospital
Diagnostic Laboratories
Oncology Centers
Research Institutions
Countries
Canada
Mexico
U.S.
Denmark
France
Germany
Italy
Norway
Spain
Sweden
UK
Australia
China
India
Japan
South Korea
Thailand
Argentina
Brazil
Kuwait
Saudi Arabia
South Africa
UAE

Pediatric Cancer Biomarker Market Companies

Name Profile # Employees HQ Website

North America pediatric cancer biomarker market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more